Posts by: Diogo Pinto

News

CENTOGENE and Denali Therapeutics are teaming up to identify and recruit Parkinson’s disease patients who carry mutations in the LRRK2 gene for future clinical trials, the companies announced. CENTOGENE will ... Read more

September 6, 2018September 12, 2018

Parkinson’s Subtypes Share Early Psychiatric Features, But Diverge as Disease Progresses, Study Suggests

News

The Parkinson’s Disease News Today forums are a place to connect with other patients, share tips and talk about the latest research. Check them out today!In the early stages, three ... Read more

August 15, 2018August 21, 2018

Higher Mortality Rates Found in Patients with Parkinson’s Dementia, Lewy Body Dementia, Study Shows

News

Patients diagnosed with Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) were found to have a mortality rate more than three times higher than the general population, according to ... Read more

August 14, 2018August 17, 2018

Study Reveals Alpha-synuclein’s Role in Parkinson’s, Lewy Body Dementia

News

Alpha-synuclein (aSyn), a protein linked to Parkinson’s disease and dementia with Lewy bodies (DLB), exerts its harmful effects by disrupting the normal function of protein production, a study has found. ... Read more

August 8, 2018August 16, 2018

Michael J. Fox Foundation Offering $7.5M in Funding for Parkinson’s Research Projects

News

The Michael J. Fox Foundation is continuing to support the advancement of Parkinson’s disease research by investing up to $7.5 million in projects proposed by investigators, the nonprofit recently announced. Funding ... Read more

August 7, 2018August 13, 2018

Insulin Resistance Under-diagnosed in Non-Diabetic Parkinson’s Patients, Study Shows

News

Insulin resistance, a condition in which cells fail to respond normally to the hormone insulin, affects almost two-thirds of non-diabetic Parkinson’s patients despite normal blood sugar levels, according to a study. This ... Read more

August 6, 2018August 8, 2018

Potential Parkinson’s Treatment, DNL201, Safe and Well-Tolerated in Phase 1 Study, Denali Says

News

Denali Therapeutics’ reports that its investigational compound for Parkinson’s disease, DNL201, was found to be safe and well-tolerated by healthy individuals in a Phase 1 clinical trial. The company is ... Read more

June 19, 2018June 19, 2018

Researchers Receive Funding to Study New Gene Linked to Parkinson’s Disease

News

A multidisciplinary research team at Purdue University in Indiana and the University of Bordeaux in France was awarded a $107,000 grant by the The Michael J. Fox Foundation for Parkinson’s Research to study the neuroprotective ability of ... Read more